Santoyo J, Suarez M A, Fernandez-Aguilar J L, Perez Daga J A, Sanchez-Perez B, Ramirez C, Aranda J M, Rodríguez-Canete A, Gonzalez-Sanchez A
Unidad de Cirugía HBP y Transplante Hepático, Servicio de Cirugía General y Digestiva, Hospital Regional Universitario Carlos Haya, Malaga, Spain.
Transplant Proc. 2006 Oct;38(8):2462-4. doi: 10.1016/j.transproceed.2006.08.015.
Our Aim was to determine the impact of cirrhosis and the preoperative MELD score on the immediate postoperative mortality and hospital stay as well as survival at 1, 5, and 8 years in liver transplantation.
Transplanted cirrhotic patients were selected who did not display some of the main known risk factors affecting recipient. Donor and surgical technique were included in this analysis. These exclusion criteria for recipient factors were emergency transplants and retransplants; for donor factors, age over 60 years, ischemia time over 10 hours, and moderate or severe steatosis on back-bench biopsy; and for surgery, prior complex upper abdominal surgery (mainly derivative and gastroduodenal surgery). Among 340 total liver transplants including 16 retransplants performed from March 1997 to December 2005, 197 patients met the selection criteria. The mean age of the recipients was 52 years (17-67) and the donors, 39 years (11-60). The transplant indication was cirrhosis in all cases: HCV in 69 cases (35%); alcohol in 55 (28%); hepatocarcinoma in 38 (19%); HBV in 19 (10%); PBC in 8 (4%), and other etiologies in 8 cases (4%). The MELD scores were divided as group 1, <10 points (33 cases = 17%); group 2, 10 to 18 points (136 cases = 69%); and group 3, >18 points (28 cases = 14%). The statistical analysis was performed with SPSS 11.0.
Postoperative mortality (up to 3 months) was 16 cases (8%). The median ICU and hospital stays were 3 and 13.5 days, respectively. Overall survivals at 1, 5, and 8 years were 89%, 80%, and 77%, respectively. The survival for the same periods according to MELD group was 97%, 97%, and 97% for group 1; 87%, 76%, and 72% for group 2; and 85%, 81%, and 81% for group 3 (P = NS). The survival according to the three main indications at 1, 5, and 8 years was: HCV, 91%, 80%, and 80%; alcohol, 87%, 80%, and 71%; and hepatocarcinoma, 84%, 80%, and 80% (P = NS). No significant differences were observed among early deaths between MELD groups or transplant indications.
In a favorable liver transplant setting including acceptable donors, absence of prior complex abdominal surgery in the recipient, and nonemergency transplants, neither the cause of the cirrhosis nor its severity, as measured preoperatively by the MELD, were predictive of early postoperative death or long-term survival.
我们的目的是确定肝硬化和术前终末期肝病模型(MELD)评分对肝移植术后即刻死亡率、住院时间以及1年、5年和8年生存率的影响。
选取未表现出一些影响受者的主要已知危险因素的肝硬化移植患者。本分析纳入了供体和手术技术因素。受者因素的这些排除标准包括急诊移植和再次移植;供体因素包括年龄超过60岁、缺血时间超过10小时以及尸检时存在中度或重度脂肪变性;手术因素包括既往复杂的上腹部手术(主要是分流术和胃十二指肠手术)。在1997年3月至2005年12月进行的340例全肝移植(包括16例再次移植)中,197例患者符合入选标准。受者的平均年龄为52岁(17 - 67岁),供体的平均年龄为39岁(11 - 60岁)。所有病例的移植指征均为肝硬化:丙型肝炎病毒(HCV)感染69例(35%);酒精性肝病55例(28%);肝细胞癌38例(19%);乙型肝炎病毒(HBV)感染19例(10%);原发性胆汁性肝硬化(PBC)8例(4%),其他病因8例(4%)。MELD评分分为1组,<10分(33例 = 17%);2组,10至18分(136例 = 69%);3组,>18分(28例 = 14%)。采用SPSS 11.0进行统计分析。
术后死亡率(至3个月)为16例(8%)。重症监护病房(ICU)和住院时间的中位数分别为3天和13.5天。1年、5年和8年的总体生存率分别为89%、80%和77%。根据MELD组划分的同期生存率,1组为97%、97%和97%;2组为87%、76%和72%;3组为85%、81%和81%(P = 无显著性差异)。根据三种主要指征划分的1年、5年和8年生存率为:HCV感染,91%、80%和80%;酒精性肝病,87%、80%和71%;肝细胞癌,84%、80%和80%(P = 无显著性差异)。MELD组或移植指征之间的早期死亡无显著差异。
在包括可接受的供体、受者无既往复杂腹部手术以及非急诊移植的有利肝移植环境中,术前通过MELD评估的肝硬化病因及其严重程度均不能预测术后早期死亡或长期生存。